Tag archive for ‘Teva Pharmaceutical Industries Ltd’
Jewish Business News On Monday, September 11th, 2017

Israeli Troubled Teva Appoints Kare Schultz CEO

  Teva‘s share price is up by more than 8% on the Tel Aviv Stock Exchange after the Israeli pharmaceutical company Named its new Kare Schultz as President and Chief Executive Officer. Kare Schultz, More...

Shai Genish On Wednesday, February 8th, 2017

Israel Police Investigate Teva Bribery Allegations

  Teva bribery: Israeli police’s National Fraud Investigation Unit have opened an investigation against Teva Pharmaceutical Industries after it reached a settlement with US authorities over charges it had More...

Jewish Business News On Monday, May 16th, 2016

Canada Business Delegation Comes to Israel Signs $87 Million in Deals

  Kathleen Wynne, Premier of Ontario, Canada,  arrived in Israel at the head of a delegation of over 100 Canadian politicians and business leaders on Sunday. The delegation included amongst others Minister More...

Jewish Business News On Wednesday, November 25th, 2015

Teva Pharmaceuticals Licenses Migraine Treatment Candidates

  Teva Pharmaceutical Industries Ltd. and UK-based Heptares Therapeutics, a subsidiary of Tokyo-based Sosei Group have announced a licensing of its migraine treatment candidates. Under the agreement Teva More...

(L-R) Robert J Coury, Mylan and Joseph Papa, Perrigo
Koby Yeshayahou On Tuesday, May 12th, 2015

Three Way Takeover Battle: Mylan Mulling Improved Offer for Perrigo – Bloomberg

Mylan (MYL) is considering an improved offer to shareholders of Perrigo (PRGO) with the aim of acquiring the company and thus heading off the hostile bid for Mylan from Teva Pharmaceutical Industries Ltd. (NYSE: More...

Jewish Business News On Wednesday, June 4th, 2014

Teva to Acquire Labrys Biologics, Inc.: Novel Migraine Prophylaxis Treatment for Up to $825 Million

–  Adds Significant New Dimension to Teva’s Growing Pain Care Franchise. Peak sales potential of $2-3 billion. – –   Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) and Labrys More...

OPKO

Teva Acquires MicroDose Therapeutx for $40 Million and Further Payments of Up to $125 Million

– Teva will pay $40 million for the lung disease drug developer and up to $125 million in milestone payments plus royalties. – – / By Jewish Business News correspondent/ Teva Pharmaceutical Industries More...

Email:

Delivered by FeedBurner